Stock 3320 CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings China Resources Pharmaceutical Group Limited

Equities

3320

HK0000311099

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:17 07/05/2024 BST 		5-day change 1st Jan Change
5.32 HKD 0.00% Intraday chart for China Resources Pharmaceutical Group Limited +4.52% +3.70%
04-24 China Resources Pharmaceutical Group Limited Announces Change of Company Secretary CI
04-18 China Resources Pharma Unit Issues 3 Billion Yuan Bonds MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • The company shows low valuation levels, with an enterprise value at 0.24 times its sales.
  • The company appears to be poorly valued given its net asset value.
  • The company has a low valuation given the cash flows generated by its activity.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED Stock China Resources Pharmaceutical Group Limited
+3.70% 4.28B
B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+33.54% 690B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.43% 546B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.05% 358B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.28% 323B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.93% 287B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.32% 235B
B+
NOVARTIS AG Stock Novartis AG
+5.79% 199B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.49% 195B
A+
AMGEN INC. Stock Amgen Inc.
+3.95% 161B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 3320 Stock
  4. Ratings China Resources Pharmaceutical Group Limited